Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
GM Canada Workers Approve C$1.1 Billion Investment Deal 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
France Targets Shein, Temu With Fast-Fashion Fees 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
OpenAI Rejects Apple Trade Secret Theft Claims 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
Trump Says ExxonMobil Among Oil Majors Planning Venezuela Return 
SpaceX Mobile Network Could Cost Up to $130 Billion, Bernstein Says 
Apple’s Phil Schiller Steps Back as Leadership Shake-Up Accelerates 
Amazon Shares Fall as FTC Plans Ad Pricing Lawsuit 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
Add as a preferred source on Google
AMES, Iowa, March 12, 2018 -- NewLink Genetics Corporation (NASDAQ:NLNK) announced today that the company will participate in the following investor conferences:
- Oppenheimer 28th Annual Healthcare Conference, March 20, 2018 in New York City
- 8th Annual Cancer Immunotherapy Conference, hosted by William Blair & Company and MaidStone Life Sciences, April 5, 2018 in New York City
At the Oppenheimer 28th Annual Healthcare Conference, NewLink Genetics’ participation will consist of one-on-one meetings with investors.
At the 8th Annual Cancer Immunotherapy Conference, NewLink Genetics’ Chairman and Chief Executive Officer, Charles J. Link, Jr, MD, will give a brief presentation during the conference segment, “Tumor Microenvironment: Metabolites/Enzymes,” beginning at 11:10 AM ET.
About NewLink Genetics Corporation
NewLink Genetics is a late-stage biopharmaceutical company focusing on discovering, developing and commercializing novel immuno-oncology product candidates to improve the lives of patients with cancer. NewLink Genetics' IDO pathway inhibitors are designed to harness multiple components of the immune system to combat cancer. For more information, please visit www.newlinkgenetics.com and follow us on Twitter @NLNKGenetics.
Investor Contact:
Lisa Miller
Director of Investor Relations
NewLink Genetics
515-598-2555
[email protected]
Media Contact:
Sharon Correia
VP, Integrated Communications
LaVoieHealthScience
617-374-8800, ext. 105
[email protected]
